Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Triple-negative breast cancers have inherent defects in DNA repair, making this cancer a rational target for therapy based on poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition. METHODS: We conducted an open-label, phase 2 study to compare the efficacy and safety of gemcitabine and carboplatin with or without iniparib, a small molecule with PARP-inhibitory activity, in patients with metastatic triple-negative breast cancer. A total of 123 patients were randomly assigned to receive gemcitabine (1000 mg per square meter of body-surface area) and carboplatin (at a dose equivalent to an area under the concentration-time curve of 2) on days 1 and 8--with or without iniparib (at a dose of 5.6 mg per kilogram of body weight) on days 1, 4, 8, and 11--every 21 days. Primary end points were the rate of clinical benefit (i.e., the rate of objective response [complete or partial response] plus the rate of stable disease for ≥6 months) and safety. Additional end points included the rate of objective response, progression-free survival, and overall survival. RESULTS: The addition of iniparib to gemcitabine and carboplatin improved the rate of clinical benefit from 34% to 56% (P=0.01) and the rate of overall response from 32% to 52% (P=0.02). The addition of iniparib also prolonged the median progression-free survival from 3.6 months to 5.9 months (hazard ratio for progression, 0.59; P=0.01) and the median overall survival from 7.7 months to 12.3 months (hazard ratio for death, 0.57; P=0.01). The most frequent grade 3 or 4 adverse events in either treatment group included neutropenia, thrombocytopenia, anemia, fatigue or asthenia, leukopenia, and increased alanine aminotransferase level. No significant difference was seen between the two groups in the rate of adverse events. CONCLUSIONS: The addition of iniparib to chemotherapy improved the clinical benefit and survival of patients with metastatic triple-negative breast cancer without significantly increased toxic effects. On the basis of these results, a phase 3 trial adequately powered to evaluate overall survival and progression-free survival is being conducted. (Funded by BiPar Sciences [now owned by Sanofi-Aventis]; ClinicalTrials.gov number, NCT00540358.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The oncology literature has indicated that positive phase II data are not necessarily replicated in the phase III setting”
In the citing paper
“Furthermore, ongoing clinical trials for metastatic TNBC are including platinum agents in their treatment regimens (4, 36–38).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [36]
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,891
Cited by
Items 201–300 of 876
Zhang, T., Prasad, P., Cai, P., He, C., Shan, D., Rauth, A. M., & Wu, X. Y. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.166 · Cited by 67
O'Kane, G. M., Connor, A. A., & Gallinger, S. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.10.007 · Cited by 67
Single cell resolution in vivo imaging of DNA damage following PARP inhibition
Yang, K. S., Kohler, R. H., Landon, M., Giedt, R., & Weissleder, R. (2015) · Scientific Reports · doi:10.1038/srep10129 · Cited by 63
Leung, M., Rosen, D. B., Fields, S. Z., Cesano, A., & Budman, D. R. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00240 · Cited by 67
Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity
Porcelli, L., Quatrale, A. E., Mantuano, P., Leo, M. G., Silvestris, N., Rolland, J., Carioggia, E., Lioce, M., Paradiso, A., & Azzariti, A. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.10.002 · Cited by 66
Thomssen, C., Pierga, J., Pritchard, K. I., Biganzoli, L., Cortés-Funes, H., Petráková, K., Kaufman, B., Duenne, A., & Smith, I. (2012) · Oncology · doi:10.1159/000336892 · Cited by 66
Molecular Pathways: PI3K Pathway Targets in Triple-Negative Breast Cancers
Gordon, V. L., & Banerji, S. O. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0274 · Cited by 66
He, Z., Wu, S., Peng, F., Zhang, Q., Luo, Y., Chen, M., & Bao, Y. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.10.004 · Cited by 66
Nanocarrier-mediated immunogenic chemotherapy for triple negative breast cancer
Liu, Y., Qiu, N., Shen, L., Liu, Q., Zhang, J., Cheng, Y., Lee, K., & Huang, L. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.040 · Cited by 66
Andreopoulou, E., & Sparano, J. A. (2013) · Current Breast Cancer Reports · doi:10.1007/s12609-012-0097-1 · Cited by 65
Kötter, A., Cornils, K., Borgmann, K., Dahm‐Daphi, J., Petersen, C., Dikomey, E., & Mansour, W. Y. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.06.008 · Cited by 65
The role of targeted therapy in ovarian cancer
Banerjee, S. N., & Kaye, S. B. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)70155-1 · Cited by 65
Targeting DNA double-strand break signalling and repair: recent advances in cancer therapy
Hühn, D., Bolck, H. A., & Sartori, A. A. (2013) · Swiss Medical Weekly · doi:10.4414/smw.2013.13837 · Cited by 44
Cancer-Associated Fibroblasts Autophagy Enhances Progression of Triple-Negative Breast Cancer Cells
Wang, M., Zhang, J., Huang, Y.-Z., Ji, S., Shao, G., Feng, S., Chen, D., Zhao, K., Wang, Z., & Wu, A. (2017) · Medical Science Monitor · doi:10.12659/msm.902870 · Cited by 64
Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer
Chun, K., Park, J. H., & Fan, S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_4 · Cited by 64
Simultaneously targeting cancer-associated fibroblasts and angiogenic vessel as a treatment for TNBC
Sharma, M., Turaga, R. C., Yuan, Y., Satyanarayana, G., Mishra, F., Bian, Z., Liu, W., Sun, L. Z., Yang, J. J., & Liu, Z. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20200712 · Cited by 64
Kuemmel, S., Campone, M., Loirat, D., López‐López, R., Beck, J. T., Laurentiis, M. D., Im, S., Kim, S.-B., Kwong, A., Steger, G. G., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3955 · Cited by 63
Successes and Limitations of Targeted Cancer Therapy in Breast Cancer
Curigliano, G., & Criscitiello, C. (2014) · Progress in tumor research · doi:10.1159/000355896 · Cited by 63
A role of intracellular mono‐ ADP ‐ribosylation in cancer biology
Scarpa, E. S., Fabrizio, G., & Girolamo, M. D. (2013) · FEBS Journal · doi:10.1111/febs.12290 · Cited by 63
Role of randomized phase III trials in an era of effective targeted therapies
Sharma, M. R., & Schilsky, R. L. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.190 · Cited by 63
PARP inhibitors in breast cancer: BRCA and beyond.
Rios, J. A., & Puhalla, S. (2011) · PubMed · Cited by 64
Poly(ADP-ribose) polymerase inhibition: a new direction for BRCAand triple-negative breast cancer?
Plummer, R. (2011) · Breast Cancer Research · doi:10.1186/bcr2877 · Cited by 54
Better Together: Targeted Combination Therapies in Breast Cancer
Zanardi, E., Bregni, G., de Braud, F., & Cosimo, S. D. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.029 · Cited by 61
Systemic therapy options in BRCA mutation-associated breast cancer
Bayraktar, S., & Glück, S. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2158-6 · Cited by 61
BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different
Burgess, M. A., & Puhalla, S. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00019 · Cited by 63
Hughes, D. L. (2017) · Organic Process Research & Development · doi:10.1021/acs.oprd.7b00235 · Cited by 61
Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer
Rummel, S. K., Varner, E. L., Shriver, C. D., & Ellsworth, R. E. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2348-2 · Cited by 60
Outcome in breast molecular subtypes according to nodal status and surgical procedures
Mazouni, C., Rimareix, F., Mathieu, M., Uzan, C., Bourgier, C., André, F., Delaloge, S., & Garbay, J.-R. (2013) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2012.06.006 · Cited by 60
Şahin, İ. H., Lowery, M. A., Stadler, Z. K., Salo‐Mullen, E. E., Iacobuzio–Donahue, C. A., Kelsen, D. P., & O'Reilly, E. M. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1153424 · Cited by 60
Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo
Park, S., Chung, Y. M., Ma, J., Yang, Q., Berek, J. S., & Hu, M. C. ‐. (2016) · Oncotarget · doi:10.18632/oncotarget.9881 · Cited by 60
Walsh, E. M., Keane, M., Wink, D. A., Callagy, G. M., & Glynn, S. A. (2016) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2017021307 · Cited by 60
Treatment of metastatic breast cancer: State-of-the-art, subtypes and perspectives
Saghir, N. S. E., Tfayli, A., Hatoum, H. A., Nachef, Z., Dinh, P., & Awada, A. H. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.01.010 · Cited by 59
Guo, J., Lv, J., Chang, S., Chen, Z., Lu, W., Xu, C., Liu, M., & Pang, X. (2016) · Oncotarget · doi:10.18632/oncotarget.9932 · Cited by 53
Mun, S. G., Choi, H. W., Lee, J. M., Lim, J. H., Ha, J. H., Kang, M., Kim, E.-J., Kang, L., & Chung, B. G. (2020) · Nano Convergence · doi:10.1186/s40580-020-0220-3 · Cited by 59
New targets in triple-negative breast cancer
Copeland, R., & KANAAN, Y. M. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00415-4 · Cited by 59
Ali, M., Kamjoo, M., Thomas, H. D., Kyle, S., Pavlovska, I., Babur, M., Telfer, B. A., Curtin, N. J., & Williams, K. J. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0356 · Cited by 58
Marinelli, B. S., Coll, C. E., Ulaner, G. A., McArthur, H. L., Gönen, M., Jochelson, M. S., & Weber, W. (2016) · PubMed · Cited by 58
Arzi, L., Farahi, A., Jafarzadeh, N., Riazi, G. H., Sadeghizadeh, M., & Hoshyar, R. (2018) · DNA and Cell Biology · doi:10.1089/dna.2018.4351 · Cited by 58
Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer
Shamseddine, A. I., & Farhat, F. (2011) · Chemotherapy · doi:10.1159/000334093 · Cited by 58
Relapsed Triple-Negative Breast Cancer: Challenges and Treatment Strategies
Guarneri, V., Dieci, M. V., & Conte, P. (2013) · Drugs · doi:10.1007/s40265-013-0091-6 · Cited by 58
Sousa, B., Ribeiro, J. M., Ribnikar, D., & Cardoso, F. (2016) · Springer eBooks · doi:10.1007/978-3-319-46356-8_24 · Cited by 57
Ulaner, G. A., Castillo, R., Wills, J., Gönen, M., & Goldman, D. A. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3709-1 · Cited by 57
Why natural killer cells in triple negative breast cancer?
Abdel-Latif, M., & Youness, R. A. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i7.464 · Cited by 57
Lønning, P. E., & Knappskog, S. (2013) · Oncogene · doi:10.1038/onc.2013.48 · Cited by 51
PARP and Cancer — If It's Broke, Don't Fix It
Carey, L., & Sharpless, N. E. (2011) · New England Journal of Medicine · doi:10.1056/nejme1012546 · Cited by 57
Targeted therapy in breast cancer: what’s new?
Li, F., Barekati, Z., Zhang, B., Liu, Z., & Zhong, X. (2011) · Swiss Medical Weekly · doi:10.4414/smw.2011.13231 · Cited by 56
Updates in the treatment of basal/triple-negative breast cancer
Shastry, M., & Yardley, D. A. (2012) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e32835c1633 · Cited by 56
Zhang, X., Huang, Y., Song, H., Canup, B. S. B., Gou, S., She, Z., Dai, F., Ke, B., & Xiao, B. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.066 · Cited by 56
Cant, A. A., Champion, S., Bhalla, R., Pimlott, S. L., & Sutherland, A. J. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201302800 · Cited by 56
Hegedűs, C., Boros, G., Fidrus, E., Kis, G. N., Antal, M., Juhász, T., Janka, E. A., Jankó, L., Paragh, G., Emri, G., et al. (2019) · Cancers · doi:10.3390/cancers12010005 · Cited by 55
Efficacy of biological agents in metastatic triple-negative breast cancer
Bramati, A., Girelli, S., Torri, V., Farina, G., Galfrascoli, E., Piva, S., Moretti, A., Dazzani, M. C., Sburlati, P., & Verde, N. M. L. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.01.003 · Cited by 55
Ma, W., Halweg, C., Menéndez, D., & Resnick, M. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118078109 · Cited by 55
Targeting the missing links for cancer therapy
Polyák, K., & Garber, J. E. (2011) · Nature Medicine · doi:10.1038/nm0311-283 · Cited by 54
Heuckmann, J. M., & Thomas, R. K. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv184 · Cited by 53
Balmañà, J., Domchek, S. M., Tutt, A. N. J., & Garber, J. E. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-11-0048 · Cited by 53
Advances in PARP inhibitors for the treatment of breast cancer
Dızdar, Ö., Arslan, Ç., & Altundağ, K. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1100168 · Cited by 52
Omics and therapy – A basis for precision medicine
Garay, J. P., & Gray, J. W. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.009 · Cited by 54
Yardley, D. A., Ward, P. J., Daniel, B. R., Eakle, J. F., Lamar, R. E., Lane, C. M., & Hainsworth, J. D. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.05.006 · Cited by 52
Aogi, K., Masuda, N., Ohno, S., Oda, T., Iwata, H., Kashiwaba, M., Fujiwara, Y., Kamigaki, S., Ito, Y., Ueno, T., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1685-x · Cited by 51
Perroud, H. A., Rico, M. J., Alasino, C. M., Queralt, F., Mainetti, L. E., Pezzotto, S. M., Rozados, V. R., & Scharovsky, O. G. (2013) · Future Oncology · doi:10.2217/fon.12.196 · Cited by 51
Synthetic Lethal Vulnerabilities of Cancer
de la Cruz, F. F., Gapp, B. V., & Nijman, S. M. B. (2014) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124511 · Cited by 53
Nitecki, R., Melamed, A., Gockley, A. A., Floyd, J. L., Krause, K. J., Coleman, R. L., Matulonis, U. A., Giordano, S. H., Lu, K. H., & Rauh‐Hain, J. A. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.03.011 · Cited by 51
The role of chemotherapy and targeted agents in patients with metastatic breast cancer
Johnston, S. R. D. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)70145-9 · Cited by 51
Ory, B., & Ellisen, L. W. (2011) · Oncotarget · doi:10.18632/oncotarget.244 · Cited by 47
Neumeister, V. M., Sullivan, C. A. W., Lindner, R. M., Lezon-Geyda, K., Li, J., Závada, J., Martel, M., Glazer, P. M., Tuck, D. P., Rimm, D. L., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2232-0 · Cited by 50
Nuclear PARP1 expression and its prognostic significance in breast cancer patients
Mazzotta, A., Partipilo, G., Summa, S. D., Giotta, F., Simone, G., & Mangia, A. (2015) · Tumor Biology · doi:10.1007/s13277-015-4465-0 · Cited by 50
Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools
Martínez-Montiel, N., Anaya-Ruíz, M., Pérez-Santos, M., & Martínez-Contreras, R. D. (2017) · Genes · doi:10.3390/genes8100217 · Cited by 50
PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer
Taylor, A. M., Chan, D. L. H., Tio, M., Patil, S. M., Traina, T. A., Robson, M. E., & Khasraw, M. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011395.pub2 · Cited by 50
Synthetic Genetic Targeting of Genome Instability in Cancer
Sajesh, B. V., Guppy, B. J., & McManus, K. J. (2013) · Cancers · doi:10.3390/cancers5030739 · Cited by 50
Takahashi, R., Toh, U., Iwakuma, N., Takenaka, M., Otsuka, H., Furukawa, M., Fujii, T., Seki, N., Kawahara, A., Kage, M., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3685 · Cited by 50
Song, H., Hedayati, M., Hobbs, R. F., Shao, C., Bruchertseifer, F., Morgenstern, A., DeWeese, T. L., & Sgouros, G. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0108 · Cited by 48
Opportunities and hurdles in the treatment of BRCA1-related breast cancer
Drost, R., & Jonkers, J. (2013) · Oncogene · doi:10.1038/onc.2013.329 · Cited by 51
Basu, B., Sandhu, S. K., & Bono, J. S. D. (2012) · Drugs · doi:10.2165/11635510-000000000-00000 · Cited by 49
Triple negative breast cancer: therapeutic and prognostic implications.
Brady-West, D., & McGrowder, D. A. (2011) · PubMed · Cited by 49
Wang, X., Ren, J., Zhang, J., Yan, Y., Jiang, N., Yu, J., Di, L., Song, G., Che, L., Jia, J., et al. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1339-2 · Cited by 48
PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and Beyond
Banerjee, S. N., & Kaye, S. B. (2011) · Current Oncology Reports · doi:10.1007/s11912-011-0193-9 · Cited by 49
Hereditary breast cancer: beyond BRCA genetic analysis; PALB2 emerges
Πουμπουρίδου, Ν., & Κroupis, C. (2012) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2011-0840 · Cited by 48
Secq, V., Villeret, J., Fina, F., Carmassi, M., Carcopino, X., Garcia, S., Metellus, I., Boubli, L., Iovanna, J., & Charpin, C. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.794 · Cited by 48
The role of targeted therapy and biomarkers in breast cancer treatment
Stopeck, A., Brown-Glaberman, U. A., Wong, H. Y., Park, B. H., Barnato, S. E., Gradishar, W. J., Hudis, C. A., & Rugo, H. S. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9496-y · Cited by 48
Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis
Clark, O. A. C., Botrel, T., Paladini, L. M., & Ferreira, M. (2014) · Core evidence · doi:10.2147/ce.s52197 · Cited by 48
The PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest
Madison, D. L., Stauffer, D. R., & Lundblad, J. R. (2011) · DNA repair · doi:10.1016/j.dnarep.2011.07.006 · Cited by 48
Personalized medicine in gastric cancer: Where are we and where are we going?
Jacome, A. A. D. A., Coutinho, A. K., de Lima, E. M., Andrade, A. C., & dos Santos, J. S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i3.1160 · Cited by 48
A snapshot of chemoresistance to PARP inhibitors
Chiarugi, A. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.10.001 · Cited by 47
Ma, J., Yang, Y., Huo, D., Wang, Z., Zhai, X., Chen, J., Sun, H., An, W., Jie, J., & Yang, P. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.04.119 · Cited by 47
Arzi, L., Riazi, G. H., Sadeghizadeh, M., Hoshyar, R., & Jafarzadeh, N. (2018) · DNA and Cell Biology · doi:10.1089/dna.2018.4248 · Cited by 47
Audeh, W. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s39765 · Cited by 46
Ohara, M., Shigematsu, H., Tsutani, Y., Emi, A., Masumoto, N., Ozaki, S., Kadoya, T., & Okada, M. (2013) · The Breast · doi:10.1016/j.breast.2013.05.003 · Cited by 46
Jacot, W., Lopez‐Crapez, E., Thézenas, S., Senal, R., Fina, F., Bibeau, F., Romieu, G., & Lamy, P. (2011) · Breast Cancer Research · doi:10.1186/bcr3079 · Cited by 46
Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1)
Zhang, Z., Chang, X., Zhang, C., Zeng, S., Liang, M., Ma, Z., Wang, Z., Huang, W., & Shen, Z. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1804382 · Cited by 46
Llombart‐Cussac, A., Bermejo, B., Villanueva, C., Delaloge, S., Morales, S. M., Balmañà, J., Amillano, K., Bonnefoi, H. R., Casas, A., Manso, L., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3616-8 · Cited by 46
DNA repair genes implicated in triple negative familial non-BRCA1/2 breast cancer predisposition.
Ollier, M., Radosevic‐Robin, N., Kwiatkowski, F., Ponelle‐Chachuat, F., Viala, S., Privat, M., Uhrhammer, N. A., Bernard-Gallon, D. J., Penault-Llorca, F. M., Bignon, Y., et al. (2015) · Europe PMC (PubMed Central) · Cited by 45
Repurposing DNA repair factors to eradicate tumor cells upon radiotherapy
Bhattacharya, S., & Asaithamby, A. (2017) · Translational Cancer Research · doi:10.21037/tcr.2017.05.22 · Cited by 45
Quintás‐Cardama, A., Qiu, Y. H., Post, S. M., Zhang, Y., Creighton, C. J., Cortes, J. E., & Kornblau, S. M. (2012) · Cancer · doi:10.1002/cncr.27568 · Cited by 45
Bao, Z., Cao, C., Geng, X., Tian, B., Wu, Y., Zhang, C., Chen, Z., Li, W., Shen, H., & Ying, S. (2015) · Oncotarget · doi:10.18632/oncotarget.5367 · Cited by 45
Pierce, A., McGowan, P. M., Cotter, M. B., Mullooly, M., O’Donovan, N., Rani, S., O’Driscoll, L., Crown, J. P., & Duffy, M. J. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.24349 · Cited by 44
Nanometric Micelles with Photo‐Triggered Cytotoxicity
Anilkumar, P., Gravel, E., Théodorou, I., Gombert, K., Thezé, B., Ducongè, F., & Doris, E. (2014) · Advanced Functional Materials · doi:10.1002/adfm.201400840 · Cited by 44
Molecular markers for cancer prognosis and treatment: Have we struck gold?
Nowsheen, S., Aziz, K., Panayiotidis, M. I., & Georgakilas, A. G. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.11.022 · Cited by 44
Padayachee, J., & Singh, M. (2020) · Nanobiomedicine · doi:10.1177/1849543520983196 · Cited by 44
Management Options in Triple-Negative Breast Cancer
Minami, C. A., Chung, D. U., & Chang, H. R. (2011) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s6562 · Cited by 45
McQuade, R. M., Stojanovska, V., Stavely, R. G., Timpani, C. A., Petersen, A. C., Abalo, R., Bornstein, J. C., Rybalka, E., & Nurgali, K. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14114 · Cited by 44
Metadata
- Authors
- O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C.
- Affiliations
- Texas Oncology (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-01-20
- Volume
- 364
- Issue
- 3
- Pages
- 205-214
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2111429259
- Cited by
- 817
- References
- 32
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 6 · 2023: 22 · 2022: 23 · 2021: 30 · 2020: 27 · 2019: 30 · 2018: 47 · 2017: 52 · 2016: 42 · 2015: 72 · 2014: 90 · 2013: 94 · 2012: 133
- FWCI
- 70.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- metastatic triple-negative breast cancer, PARP inhibition, gemcitabine, carboplatin, combination chemotherapy, DNA repair deficiency, clinical benefit, progression-free survival, overall survival, adverse events, neutropenia, thrombocytopenia, drug safety and efficacy
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Gemcitabine, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Breast Neoplasms, Deoxycytidine, Female, Humans, Neoplasm Metastasis, Survival Analysis, Carboplatin, Cross-Over Studies, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.